Disease management

Harald Rinde, MD, MBA, Anne Rubin, MBA. Cost-effectiveness of the cardiovascular marker ST2 in providing risk stratification after acute heart failure.[ISPOR 14th Annual European Congress, Madrid] Nov 2011.

Harald Rinde.Chapter 8: Disease Management in Pharmaceutical Companies” Editor: J. Couch Epilogue: James, Bill First, Foreword: Philip Caper [The Health Care Professional’s Guide to Disease Management: Patient-Centered Care for the 21st Century.  Aspen Publications, USA] First edition: 1997; Second edition: 1998

A.-P. Holtorf (1997) Disease Management – Sourcing and managing the underlying information. Invited lecture at the FT World pharmaceutical conference, London, 24/25. Mar. 97. The paper was published in the Journal ‘Managed Care Europe’ in April 1997.

A.-P. Holtorf (1996) Moderation of the Symposium ‘Disease management im vernetzten Gesundheitswesen’ (Disease Management in the Integrated Health Care System) including lecture ‘ Integriertes Gesundheitsmanagement; Herausforderung für die Pharmaindustrie’ (Integrated Healthcare Management; Challenge for the Pharmaceutical Industry); 14. October 1996 in Munich – as day 1 of the meeting ‘Disease Management und Online-Medien für das Pharma Produkt Management’ (Disease Management and online media for the pharmaceutical product management).

A.-P. Holtorf (1996) Integriertes Gesundheitsmanagement und Information: Einfluss auf die pharmazeutische Industrie (Disease Management and Information: Impact on the Pharmaceutical Industry), Invited lecture, IMS Pharma Gesprächsrunde, Frankfurt a.M./Germany, 7/8.Nov.1996.